Morgan Stanley Maintains Overweight on Silence Therapeutics, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz has maintained an Overweight rating on Silence Therapeutics (NASDAQ:SLN) and increased the price target from $29 to $45.
March 14, 2024 | 4:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has maintained an Overweight rating on Silence Therapeutics and raised the price target from $29 to $45.
The upgrade in the price target by a reputable analyst like Michael Ulz from Morgan Stanley is a strong positive signal for investors, indicating a bullish outlook on Silence Therapeutics. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100